EBI Expands Bone Growth Portfolio with Xstim Acquisition
Event summary
- EBI acquired Xstim, a division of Precision Medical Products Inc., on June 18, 2026.
- Xstim's wearable, non-invasive spine fusion stimulation technology complements EBI's existing bone growth stimulation portfolio.
- EBI is now the only pure-play bone growth stimulation company with a comprehensive range of solutions.
- The acquisition strengthens EBI's R&D pipeline and expands treatment options for physicians and patients.
The big picture
EBI's acquisition of Xstim reinforces its position as the only pure-play bone growth stimulation company, expanding its portfolio to include next-generation wearable technology. This move aligns with broader industry trends toward non-invasive, patient-friendly solutions in orthopedic care. Avista Healthcare Partners, EBI's private equity backer, continues to invest in growth-oriented healthcare businesses, leveraging strategic acquisitions to enhance scale and innovation.
What we're watching
- Integration Challenges
- How EBI will integrate Xstim's technology into its existing portfolio and maintain operational efficiency.
- Market Response
- Whether the acquisition will solidify EBI's market leadership and drive competitive differentiation.
- Regulatory Approvals
- The pace at which EBI can secure additional regulatory clearances for Xstim's technology in new markets.
Related topics